LAMZEDE (velmanase alfa-tycv)
METABOLIC DISEASE ENZYME REPLACEMENT, ALPHA-MANNOSIDOSIS · ALPHA-MANNOSIDOSIS
CHIESI USA, INC
Drug class
Metabolic Disease Enzyme Replacement, Alpha-Mannosidosis
Metabolic Disease Enzyme Replacement, Alpha-Mannosidosis represents a specialized disease-specific grouping within the broader pharmacological class of lysosomal enzyme replacement therapies. Read more about Metabolic Disease Enzyme Replacement, Alpha-Mannosidosis
1 drugs in this class 1 manufacturers
Drugs in Metabolic Disease Enzyme Replacement, Alpha-Mannosidosis
Filter & compare in the drug finder →
Opens the drug finder with Metabolic Disease Enzyme Replacement, Alpha-Mannosidosis preselected. Add indication or manufacturer filters there.
Metabolic Disease Enzyme Replacement, Alpha-Mannosidosis represents a specialized disease-specific grouping within the broader pharmacological class of lysosomal enzyme replacement therapies.
It consists of recombinant human alpha-mannosidase, such as velmanase alfa, designed to supply an exogenous form of the enzyme that internalizes into cells via mannose-6-phosphate receptors and degrades accumulated mannose-rich oligosaccharides inside lysosomes.
Clinically, these agents are indicated to treat the non-central nervous system manifestations of alpha-mannosidosis, a rare inherited lysosomal storage disorder caused by pathogenic variants in the MAN2B1 gene.
-
drugs.com
Metabolic Disease Enzyme Replacement, Alpha-Mannosidosis represents a specialized disease-specific grouping within the broader pharmacological class of lysosomal enzyme replacement therapies
-
fda.gov
Metabolic Disease Enzyme Replacement, Alpha-Mannosidosis represents a specialized disease-specific grouping within the broader pharmacological class of lysosomal enzyme replacement therapies Clinically, these agents are indicated to treat the non-central nervous system manifestations of alpha-mannosidosis, a rare inherited lysosomal storage disorder caused by pathogenic variants in the MAN2B1 gene
-
fda.gov
It consists of recombinant human alpha-mannosidase, such as velmanase alfa, designed to supply an exogenous form of the enzyme that internalizes into cells via mannose-6-phosphate receptors and degrades accumulated mannose-rich oligosaccharides inside lysosomes Clinically, these agents are indicated to treat the non-central nervous system manifestations of alpha-mannosidosis, a rare inherited lysosomal storage disorder caused by pathogenic variants in the MAN2B1 gene
-
nih.gov
It consists of recombinant human alpha-mannosidase, such as velmanase alfa, designed to supply an exogenous form of the enzyme that internalizes into cells via mannose-6-phosphate receptors and degrades accumulated mannose-rich oligosaccharides inside lysosomes
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.